RAP1A, member of RAS oncogene familyGenealiases: C21KG · G-22K · KREV-1 · KREV1 · RAP1 · SMGP21
Q-omics provides the consensus-scored RAP1A profile across patient tissues and cancer cell-line models. RAP1A expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, RAP1A is differentially expressed in 16, with the highest sampling consensus in KICH. Additionally, RAP1A protein abundance shows 28,443 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight LIHC, KICH, and LSCC as cancer lineages where RAP1A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RAP1A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RAP1A survival associations across molecular data types. RAP1A RNA expression shows survival associations in the most cancer types (21), followed by mutation status (4) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RAP1A RNA expression–survival associations across cancer types. High RAP1A expression shows unfavorable associations in LIHC, LGG and KICH, but favorable associations in KIRC, SKCM and CHOL. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for RAP1A RNA expression.
This table summarizes RAP1A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 9. The strongest signals are observed in KICH for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for RAP1A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RAP1A shows lower tumor expression in KICH, COAD, LUAD, BLCA and LUSC and higher tumor expression in LIHC. The KICH box plot shows higher RAP1A RNA expression in normal versus tumor tissue (log2 FC = −1.297, t-test p < 0.001).
This table shows molecular features associated with RAP1A in patient tissues and cancer cell lines. In patient samples, RAP1A shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, RAP1A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BONE.
